【藥品庫存】 藥品安全警訊 (藥品回收)：本品因廠商自主回收，剩餘庫存保留給已經開立處方箋的個案，不便之處，請多包涵。更新日期：2021/8/24。

As an aid to smoking cessation treatment
#仿單變更2021

Varenicline binds with high affinity and selectivity at α4β2 neuronal nicotinic acetylcholine receptors. This binding produces agonist activity at a sub-type of the nicotinic receptor, but at a significantly lower level than nicotine. Varenicline also prevents nicotine binding to α4β2 receptors, which prevents stimulation of the central nervous mesolimbic dopamine system.

High bioavailability; protein binding: <20%; Varenicline undergoes minimal metabolism with 92% excreted unchanged in the urine. Elimination half-life：~24 hour

Hypersensitivity to the active substance or to any excipients.

C

Avoided

Neutropenia (most common), thrombocytopenia, anemia, headache, insomnia, abdominal pain, diarrhea, nausea, vomiting.

initial, 0.5 mg ORALLY once daily for days 1 through 3, then 0.5 mg twice daily for days 4 through 7, then 1 mg twice daily; duration of treatment is 12 weeks. Varenicline should be taken after eating, with a full glass of water.